Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
ABVC BIOPHARMA, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
- Exchange
- nasdaq
- Notice
- extension granted
- Deficiency
- minimum bid price
- Rules
- 5550(a)(2)
Exact text from the filing
January 9, 2025, ABVC BioPharma, Inc. (the "Company") received a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement of $1.00 per share, as
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
ABVC BIOPHARMA, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
- Exchange
- nasdaq
- Notice
- extension granted
- Deficiency
- minimum bid price
- Rules
- 5550(a)(2)
Exact text from the filing
January 9, 2025, ABVC BioPharma, Inc. (the "Company") received a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement of $1.00 per share, as outlined in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). On July 12, 2024, the Company disclosed that Nasdaq had informed it that its stock had failed to maintain the minimum bid price over the preceding 30 business days. At that time, the Company was given until January 6, 2025, to regain compliance. The current extension was granted based on the Company’s adherence to other l
View on SEC.gov